According to a recent study, in patients with frontotemporal dementia (FTD), epileptic seizures are significantly more common than previously known. The discovery deepens understanding of the symptoms ...
Passage Bio, Inc. announced interim results from its PBFT02 clinical trial for frontotemporal dementia (FTD) patients with the GRN mutation, revealing significant increases in cerebrospinal fluid (CSF ...
A new study reveals that gut bacteria may play a key role in triggering ALS and frontotemporal dementia. Harmful sugars ...
LONDON--(BUSINESS WIRE)--AviadoBio, a pioneering gene therapy company dedicated to developing and delivering potentially transformative medicines for neurodegenerative disorders, today announced that ...
(RTTNews) - NKGen Biotech (NKGN), Friday revealed the administration of the first dose of its autologous NK cell therapy, troculeucel, to a frontotemporal dementia or FTD patient under an FDA-cleared ...
- AVB-101 is an investigational one-time therapy designed to deliver a functional copy of the GRN gene directly to the brain, thereby potentially restoring progranulin levels and stopping disease ...
How can apathy be managed in an individual with frontotemporal dementia? Frontotemporal dementia or frontotemporal degeneration (FTD) refers to a range of disorders that impact the brain’s frontal ...
The most common genetic cause of the brain diseases frontotemporal dementia (FTD) and amyotrophic lateral sclerosis (ALS) is a mutation in the C9orf72 gene. Researchers from VIB and UAntwerp, headed ...
Hosted on MSN
Q&A: New diagnostics and treatments for ALS and dementia—a key protein may point the way
The two neurodegenerative diseases could not appear more different. Amyotrophic lateral sclerosis (ALS), sometimes called Lou Gehrig's disease, affects the muscles, ultimately paralyzing people with ...
The last time I wrote an article on Alector, Inc. (ALEC), I analyzed its enormous potential in using its TREM2 receptor drug AL002 being studied in the phase 2 INVOKE-2 trial, which was targeting ...
Most people with neurodegenerative disease have a mix of protein pathologies in their brain, but there is no easy way to identify them all separately. Indeed, clinicians are urgently awaiting blood ...
SOLANA BEACH, Calif., April 16, 2024 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (CLPT) (the “Company”), a global device, cell, and gene therapy-enabling company offering precise navigation to the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results